Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 18/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.43 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470155 | 0.83 | CHEK1 (0.70) | CHEK1RAB9AGRM2MAP3K7JAK2 | |
| SCHEMBL5470798 | 0.81 | CHEK1 (1.00) | CHEK1 | |
| SCHEMBL5475521 | 0.81 | CHEK1 (0.52) | CHEK1 | |
| SCHEMBL5478918 | 0.80 | CHEK1 (0.67) | CHEK1GRM2MAP3K7JAK2KDR | |
| SCHEMBL5475765 | 0.76 | CHEK1 (0.54) | CHEK1RAB9AGRM2MAP3K7JAK2 | |
| SCHEMBL5475762 | 0.76 | CHEK1 (0.54) | CHEK1RAB9AGRM2MAP3K7JAK2 | |
| SCHEMBL5497035 | 0.74 | CHEK1 (0.62) | CHEK1GRM2MAP3K7JAK2KDR | |
| SCHEMBL5478067 | 0.74 | CHEK1 (0.58) | CHEK1RAB9AGRM2MAP3K7JAK2 | |
| SCHEMBL5472624 | 0.74 | CHEK1 (0.59) | CHEK1RAB9AGRM2MAP3K7JAK2 | |
| SCHEMBL14492158 | 0.74 | CHEK1 (0.62) | CHEK1RAB9AGRM2MAP3K7JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | claimed |
| JP-2006520397-A | — | — | 2006-09-07 | — | — | JP | claimed |
| EP-1613625-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004081008-A1 | NOVEL FUSED TRIAZOLONES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2004-09-23 | — | — | WO | claimed |
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149560-A1 | Novel fused triazolones and the uses thereof | TP53, BRCA1, KLK3 | CHEK1 13/4885RAB9A 1633/4885GRM2 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.